Z-domain protein nano-bio interfaced MRI visible anti-program death ligand-1 nanoconjugates for enhanced local immune checkpoint inhibitor immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers10.1172/jci.insight.126908 ↗
2. Immune checkpoint blockade in hepatocellular carcinoma10.1159/000367758 ↗
3. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-04010.1200/jco.2015.33.18_suppl.lba101 ↗
4. Immunological landscape and immunotherapy of hepatocellular carcinoma10.1038/nrgastro.2015.173 ↗
5. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches10.1136/gutjnl-2014-307990 ↗
6. Potentiality of immunotherapy against hepatocellular carcinoma10.3748/wjg.v21.i36.10314 ↗
7. Jiang · Mol. Cancer · 2019 · 18
8. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer10.1158/0008-5472.CAN-13-1550 ↗
9. Munari · J. Thorac. Oncol. · 2019 · 14
10. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity10.1038/s41589-018-0161-x ↗
11. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors10.1007/s40262-019-00748-2 ↗
12. Clinical pharmacokinetics of therapeutic monoclonal antibodies10.2165/11531280-000000000-00000 ↗
13. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
14. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
15. Enhancing cancer immunotherapy with nanomedicine10.1038/s41577-019-0269-6 ↗
16. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
17. Pathogenic CARD11 mutations affect B cell development and differentiation through a noncanonical pathway
18. An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy10.1021/acs.nanolett.0c00953 ↗
19. Jiang · Nat. Commun. · 2021 · 12
20. Wilhelm · Nat. Rev. Mater. · 2016 · 1
21. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
22. Bertrand · Nat. Commun. · 2017 · 8
23. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies10.1016/j.ejca.2020.01.003 ↗
24. Pointing in the right direction: controlling the orientation of proteins on nanoparticles improves targeting efficiency10.1021/acs.nanolett.8b04916 ↗
25. Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform10.1016/j.biomaterials.2012.03.055 ↗
26. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona10.1038/s41565-018-0171-6 ↗
27. Oriented immobilization to nanoparticles enhanced the therapeutic efficacy of antibody drugs10.1016/j.actbio.2019.01.011 ↗
28. Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles10.1016/j.nano.2018.09.007 ↗
29. Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers10.1016/j.jim.2006.03.007 ↗
30. Antibodies in the breakdown lane10.1038/nbt1005-1232 ↗
31. Structure and optimization of checkpoint inhibitors10.3390/cancers12010038 ↗
32. IgG subclasses and allotypes: from structure to effector functions10.3389/fimmu.2014.00520 ↗
33. The influence of covalent immobilization conditions on antibody accessibility on nanoparticles10.1039/C7AN01424D ↗
34. Fluid shear stress promotes autophagy in hepatocellular carcinoma cells10.7150/ijbs.27055 ↗
35. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells10.3390/ijms22168755 ↗
36. Quantifying colocalization by correlation: The Pearson correlation coefficient is superior to the Mander’s overlap coefficient10.1002/cyto.a.20896 ↗
37. FcγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy10.3389/fimmu.2019.00292 ↗
38. Immune-based therapies for hepatocellular carcinoma10.1038/s41388-020-1249-9 ↗
39. Biomarkers to predict immune-related adverse events with checkpoint inhibitors10.1200/JCO.2019.37.8_suppl.131 ↗
40. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma10.1038/s41575-020-00395-0 ↗
41. Local immunotherapy of cancer: innovative approaches to harnessing tumor-specific immune responses10.1093/jnci/djx097 ↗
42. Effective delivery of antigen–encapsulin nanoparticle fusions to dendritic cells leads to antigen-specific cytotoxic T cell activation and tumor rejection10.1021/acsnano.5b08084 ↗
43. Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation10.1097/00054725-200606000-00004 ↗
44. QuPath: Open source software for digital pathology image analysis10.1038/s41598-017-17204-5 ↗